Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 1932 | 641571-10-0 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 4 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 21.58 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 29, 2007 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cytogenetic analysis abnormal | 492.32 | 15.84 | 102 | 20407 | 644 | 50583971 |
Peripheral arterial occlusive disease | 351.86 | 15.84 | 106 | 20403 | 3431 | 50581184 |
Electrocardiogram QT prolonged | 323.23 | 15.84 | 222 | 20287 | 51664 | 50532951 |
Blast crisis in myelogenous leukaemia | 213.57 | 15.84 | 48 | 20461 | 464 | 50584151 |
Second primary malignancy | 204.60 | 15.84 | 84 | 20425 | 6830 | 50577785 |
Chronic myeloid leukaemia transformation | 191.11 | 15.84 | 34 | 20475 | 78 | 50584537 |
Drug resistance | 187.87 | 15.84 | 109 | 20400 | 18880 | 50565735 |
Lipase increased | 174.83 | 15.84 | 80 | 20429 | 8461 | 50576154 |
Philadelphia chromosome positive | 155.19 | 15.84 | 35 | 20474 | 344 | 50584271 |
Rash | 149.22 | 15.84 | 451 | 20058 | 437020 | 50147595 |
Pleural effusion | 148.72 | 15.84 | 174 | 20335 | 81280 | 50503335 |
Peripheral artery stenosis | 113.55 | 15.84 | 29 | 20480 | 500 | 50584115 |
Blood bilirubin increased | 113.24 | 15.84 | 98 | 20411 | 31940 | 50552675 |
Bone pain | 112.38 | 15.84 | 116 | 20393 | 47113 | 50537502 |
Intermittent claudication | 112.08 | 15.84 | 37 | 20472 | 1618 | 50582997 |
Myocardial infarction | 110.31 | 15.84 | 157 | 20352 | 88870 | 50495745 |
Malignant neoplasm progression | 105.57 | 15.84 | 134 | 20375 | 67990 | 50516625 |
Off label use | 91.63 | 15.84 | 39 | 20470 | 474387 | 50110228 |
Thrombocytopenia | 87.92 | 15.84 | 173 | 20336 | 127500 | 50457115 |
Arteriosclerosis | 84.20 | 15.84 | 50 | 20459 | 9027 | 50575588 |
Acute myocardial infarction | 80.86 | 15.84 | 78 | 20431 | 29195 | 50555420 |
Chronic myeloid leukaemia recurrent | 78.13 | 15.84 | 18 | 20491 | 196 | 50584419 |
Platelet count decreased | 77.35 | 15.84 | 143 | 20366 | 100583 | 50484032 |
Pancreatitis | 75.97 | 15.84 | 90 | 20419 | 42524 | 50542091 |
Myalgia | 70.97 | 15.84 | 156 | 20353 | 124163 | 50460452 |
White blood cell count increased | 70.05 | 15.84 | 86 | 20423 | 42154 | 50542461 |
Death | 69.44 | 15.84 | 288 | 20221 | 325091 | 50259524 |
Angina pectoris | 63.48 | 15.84 | 65 | 20444 | 26123 | 50558492 |
Labelled drug-food interaction medication error | 62.52 | 15.84 | 11 | 20498 | 23 | 50584592 |
Acute lymphocytic leukaemia recurrent | 61.85 | 15.84 | 25 | 20484 | 1950 | 50582665 |
Platelet count increased | 60.73 | 15.84 | 49 | 20460 | 14491 | 50570124 |
Pruritus | 59.67 | 15.84 | 250 | 20259 | 283318 | 50301297 |
Normal newborn | 57.26 | 15.84 | 35 | 20474 | 6656 | 50577959 |
Peripheral vascular disorder | 55.68 | 15.84 | 32 | 20477 | 5435 | 50579180 |
Condition aggravated | 54.76 | 15.84 | 26 | 20483 | 297032 | 50287583 |
Pancytopenia | 54.35 | 15.84 | 111 | 20398 | 83919 | 50500696 |
Blast cell crisis | 52.86 | 15.84 | 11 | 20498 | 71 | 50584544 |
Joint swelling | 52.55 | 15.84 | 17 | 20492 | 245269 | 50339346 |
Haematotoxicity | 51.96 | 15.84 | 35 | 20474 | 7860 | 50576755 |
Rheumatoid arthritis | 49.10 | 15.84 | 11 | 20498 | 202539 | 50382076 |
Polymerase chain reaction positive | 48.54 | 15.84 | 10 | 20499 | 61 | 50584554 |
Therapeutic response delayed | 48.07 | 15.84 | 15 | 20494 | 546 | 50584069 |
Pericardial effusion | 47.18 | 15.84 | 55 | 20454 | 25534 | 50559081 |
Myocardial ischaemia | 46.10 | 15.84 | 38 | 20471 | 11575 | 50573040 |
Hyperbilirubinaemia | 45.90 | 15.84 | 35 | 20474 | 9535 | 50575080 |
Splenomegaly | 45.61 | 15.84 | 35 | 20474 | 9625 | 50574990 |
Cerebrovascular accident | 44.35 | 15.84 | 110 | 20399 | 94570 | 50490045 |
Drug ineffective | 44.29 | 15.84 | 177 | 20332 | 819156 | 49765459 |
Carotid artery stenosis | 43.72 | 15.84 | 26 | 20483 | 4705 | 50579910 |
Systemic lupus erythematosus | 42.43 | 15.84 | 4 | 20505 | 140618 | 50443997 |
Blood glucose increased | 42.36 | 15.84 | 91 | 20418 | 71233 | 50513382 |
Arthropathy | 41.58 | 15.84 | 7 | 20502 | 157899 | 50426716 |
Anaemia | 40.04 | 15.84 | 205 | 20304 | 252251 | 50332364 |
Exposure via father | 39.91 | 15.84 | 11 | 20498 | 257 | 50584358 |
Arterial disorder | 39.16 | 15.84 | 15 | 20494 | 1014 | 50583601 |
Dry skin | 39.16 | 15.84 | 66 | 20443 | 43125 | 50541490 |
Drug hypersensitivity | 39.05 | 15.84 | 27 | 20482 | 250983 | 50333632 |
Coronary artery disease | 37.61 | 15.84 | 53 | 20456 | 29673 | 50554942 |
Exposure via partner | 37.53 | 15.84 | 9 | 20500 | 118 | 50584497 |
Xanthelasma | 37.40 | 15.84 | 8 | 20501 | 60 | 50584555 |
Thrombocytosis | 34.93 | 15.84 | 23 | 20486 | 4973 | 50579642 |
Diabetes mellitus | 34.36 | 15.84 | 67 | 20442 | 48966 | 50535649 |
Chronic myeloid leukaemia | 34.34 | 15.84 | 17 | 20492 | 2139 | 50582476 |
Palpitations | 33.41 | 15.84 | 99 | 20410 | 94407 | 50490208 |
Amylase increased | 33.19 | 15.84 | 23 | 20486 | 5407 | 50579208 |
Bone marrow failure | 33.10 | 15.84 | 48 | 20461 | 27576 | 50557039 |
Glossodynia | 33.04 | 15.84 | 4 | 20505 | 115565 | 50469050 |
Leukaemia recurrent | 32.94 | 15.84 | 14 | 20495 | 1240 | 50583375 |
Gene mutation identification test positive | 32.61 | 15.84 | 8 | 20501 | 116 | 50584499 |
Basophil count increased | 31.21 | 15.84 | 12 | 20497 | 820 | 50583795 |
Arterial occlusive disease | 30.88 | 15.84 | 21 | 20488 | 4787 | 50579828 |
Skin disorder | 30.62 | 15.84 | 43 | 20466 | 23987 | 50560628 |
Food interaction | 30.22 | 15.84 | 11 | 20498 | 645 | 50583970 |
Hypercholesterolaemia | 30.10 | 15.84 | 30 | 20479 | 11673 | 50572942 |
Abdominal pain upper | 30.01 | 15.84 | 136 | 20373 | 159173 | 50425442 |
Acute coronary syndrome | 29.76 | 15.84 | 27 | 20482 | 9347 | 50575268 |
Concomitant disease progression | 29.27 | 15.84 | 15 | 20494 | 2030 | 50582585 |
Peripheral ischaemia | 28.24 | 15.84 | 19 | 20490 | 4257 | 50580358 |
Peripheral artery occlusion | 27.97 | 15.84 | 12 | 20497 | 1087 | 50583528 |
Toxicity to various agents | 27.89 | 15.84 | 27 | 20482 | 212472 | 50372143 |
Cytopenia | 27.32 | 15.84 | 25 | 20484 | 8750 | 50575865 |
Hypotension | 26.43 | 15.84 | 34 | 20475 | 235435 | 50349180 |
Product use issue | 26.12 | 15.84 | 14 | 20495 | 149461 | 50435154 |
Gamma-glutamyltransferase increased | 25.18 | 15.84 | 44 | 20465 | 29579 | 50555036 |
Concomitant disease aggravated | 25.09 | 15.84 | 23 | 20486 | 8068 | 50576547 |
Acute kidney injury | 24.51 | 15.84 | 34 | 20475 | 228024 | 50356591 |
Pregnancy of partner | 24.48 | 15.84 | 5 | 20504 | 29 | 50584586 |
Musculoskeletal stiffness | 24.01 | 15.84 | 11 | 20498 | 128470 | 50456145 |
Pain in extremity | 23.58 | 15.84 | 190 | 20319 | 272675 | 50311940 |
Abdominal pain | 23.49 | 15.84 | 170 | 20339 | 236058 | 50348557 |
Blast cell count increased | 23.43 | 15.84 | 8 | 20501 | 388 | 50584227 |
Wound | 23.22 | 15.84 | 7 | 20502 | 105787 | 50478828 |
Sinusitis | 23.16 | 15.84 | 21 | 20488 | 170537 | 50414078 |
Keratosis pilaris | 22.77 | 15.84 | 5 | 20504 | 43 | 50584572 |
Alanine aminotransferase increased | 22.64 | 15.84 | 83 | 20426 | 88276 | 50496339 |
Neoplasm malignant | 22.51 | 15.84 | 37 | 20472 | 23678 | 50560937 |
Haemolytic transfusion reaction | 22.24 | 15.84 | 4 | 20505 | 10 | 50584605 |
Muscle spasms | 22.02 | 15.84 | 105 | 20404 | 125448 | 50459167 |
Cardiac failure | 21.69 | 15.84 | 74 | 20435 | 75966 | 50508649 |
Collateral circulation | 21.46 | 15.84 | 4 | 20505 | 13 | 50584602 |
Lower respiratory tract infection | 21.44 | 15.84 | 6 | 20503 | 95195 | 50489420 |
Therapeutic response decreased | 21.18 | 15.84 | 54 | 20455 | 47177 | 50537438 |
Chest pain | 20.98 | 15.84 | 133 | 20376 | 176749 | 50407866 |
Alopecia | 20.82 | 15.84 | 170 | 20339 | 244877 | 50339738 |
Confusional state | 20.70 | 15.84 | 27 | 20482 | 185901 | 50398714 |
Blood lactate dehydrogenase increased | 20.59 | 15.84 | 32 | 20477 | 19530 | 50565085 |
Gangrene | 19.99 | 15.84 | 16 | 20493 | 4676 | 50579939 |
Delivery | 19.51 | 15.84 | 8 | 20501 | 647 | 50583968 |
Overdose | 19.48 | 15.84 | 8 | 20501 | 99719 | 50484896 |
Pancreatic enzymes increased | 19.36 | 15.84 | 8 | 20501 | 660 | 50583955 |
Intentional product use issue | 18.98 | 15.84 | 4 | 20505 | 76914 | 50507701 |
Hepatic infection | 18.79 | 15.84 | 7 | 20502 | 438 | 50584177 |
Hepatic function abnormal | 18.59 | 15.84 | 41 | 20468 | 32640 | 50551975 |
Impaired healing | 18.57 | 15.84 | 3 | 20506 | 69783 | 50514832 |
Hypersensitivity | 18.54 | 15.84 | 37 | 20472 | 215124 | 50369491 |
Dyslipidaemia | 18.53 | 15.84 | 17 | 20492 | 5971 | 50578644 |
Leukocytosis | 18.49 | 15.84 | 33 | 20476 | 22546 | 50562069 |
Transaminases increased | 18.26 | 15.84 | 37 | 20472 | 27787 | 50556828 |
Hyperglycaemia | 17.77 | 15.84 | 43 | 20466 | 36362 | 50548253 |
Atrial fibrillation | 17.77 | 15.84 | 85 | 20424 | 101660 | 50482955 |
Discomfort | 17.72 | 15.84 | 11 | 20498 | 108369 | 50476246 |
Oxygen saturation decreased | 17.68 | 15.84 | 4 | 20505 | 73244 | 50511371 |
Exposure during pregnancy | 17.52 | 15.84 | 14 | 20495 | 121001 | 50463614 |
Angiopathy | 17.44 | 15.84 | 14 | 20495 | 4108 | 50580507 |
Gene mutation | 17.26 | 15.84 | 9 | 20500 | 1262 | 50583353 |
Haemoglobin decreased | 17.20 | 15.84 | 99 | 20410 | 127117 | 50457498 |
Jaundice | 17.17 | 15.84 | 35 | 20474 | 26394 | 50558221 |
Calculus bladder | 17.12 | 15.84 | 7 | 20502 | 562 | 50584053 |
Stomatitis | 16.97 | 15.84 | 10 | 20499 | 101334 | 50483281 |
Coronary artery stenosis | 16.95 | 15.84 | 14 | 20495 | 4275 | 50580340 |
Swelling | 16.92 | 15.84 | 35 | 20474 | 200837 | 50383778 |
Hyponatraemia | 16.80 | 15.84 | 9 | 20500 | 96130 | 50488485 |
Vertebral artery stenosis | 16.12 | 15.84 | 4 | 20505 | 61 | 50584554 |
Extremity necrosis | 16.03 | 15.84 | 9 | 20500 | 1462 | 50583153 |
Fluid retention | 15.96 | 15.84 | 51 | 20458 | 50598 | 50534017 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cytogenetic analysis abnormal | 424.11 | 15.06 | 96 | 22151 | 474 | 29551806 |
Blast crisis in myelogenous leukaemia | 373.71 | 15.06 | 86 | 22161 | 463 | 29551817 |
Second primary malignancy | 371.20 | 15.06 | 152 | 22095 | 6553 | 29545727 |
Peripheral arterial occlusive disease | 368.49 | 15.06 | 140 | 22107 | 4936 | 29547344 |
Electrocardiogram QT prolonged | 350.98 | 15.06 | 258 | 21989 | 35879 | 29516401 |
Drug resistance | 220.77 | 15.06 | 159 | 22088 | 21381 | 29530899 |
Intermittent claudication | 218.17 | 15.06 | 75 | 22172 | 1970 | 29550310 |
Pleural effusion | 208.01 | 15.06 | 263 | 21984 | 71645 | 29480635 |
Angina pectoris | 207.38 | 15.06 | 170 | 22077 | 27680 | 29524600 |
Rash | 162.63 | 15.06 | 406 | 21841 | 189413 | 29362867 |
Lipase increased | 156.17 | 15.06 | 90 | 22157 | 8247 | 29544033 |
Myocardial infarction | 148.11 | 15.06 | 283 | 21964 | 110013 | 29442267 |
Death | 137.25 | 15.06 | 563 | 21684 | 341521 | 29210759 |
Chronic myeloid leukaemia transformation | 131.30 | 15.06 | 29 | 22218 | 125 | 29552155 |
Coronary artery stenosis | 125.51 | 15.06 | 79 | 22168 | 8494 | 29543786 |
Off label use | 123.08 | 15.06 | 37 | 22210 | 300763 | 29251517 |
Philadelphia chromosome positive | 115.02 | 15.06 | 30 | 22217 | 290 | 29551990 |
Drug intolerance | 109.24 | 15.06 | 157 | 22090 | 48222 | 29504058 |
Chronic myeloid leukaemia recurrent | 106.03 | 15.06 | 25 | 22222 | 152 | 29552128 |
Blood bilirubin increased | 96.27 | 15.06 | 123 | 22124 | 33770 | 29518510 |
Pancreatitis | 92.95 | 15.06 | 122 | 22125 | 34392 | 29517888 |
Peripheral artery stenosis | 90.09 | 15.06 | 31 | 22216 | 816 | 29551464 |
Malignant neoplasm progression | 87.50 | 15.06 | 180 | 22067 | 73679 | 29478601 |
Acute kidney injury | 82.25 | 15.06 | 49 | 22198 | 265218 | 29287062 |
White blood cell count increased | 82.10 | 15.06 | 120 | 22127 | 37396 | 29514884 |
Arterial disorder | 82.09 | 15.06 | 31 | 22216 | 1072 | 29551208 |
Acute myocardial infarction | 79.78 | 15.06 | 136 | 22111 | 48302 | 29503978 |
Myocardial ischaemia | 77.92 | 15.06 | 77 | 22170 | 15951 | 29536329 |
Peripheral vascular disorder | 76.82 | 15.06 | 46 | 22201 | 4521 | 29547759 |
Platelet count decreased | 75.13 | 15.06 | 210 | 22037 | 104462 | 29447818 |
Coronary artery disease | 74.00 | 15.06 | 125 | 22122 | 44065 | 29508215 |
Toxicity to various agents | 71.52 | 15.06 | 21 | 22226 | 173640 | 29378640 |
Hypotension | 65.88 | 15.06 | 32 | 22215 | 194322 | 29357958 |
Abdominal pain upper | 65.66 | 15.06 | 143 | 22104 | 60850 | 29491430 |
Concomitant disease aggravated | 58.52 | 15.06 | 40 | 22207 | 4938 | 29547342 |
Chest pain | 57.49 | 15.06 | 200 | 22047 | 111773 | 29440507 |
Acute coronary syndrome | 55.84 | 15.06 | 57 | 22190 | 12268 | 29540012 |
Gene mutation identification test positive | 55.60 | 15.06 | 14 | 22233 | 116 | 29552164 |
Polymerase chain reaction positive | 55.39 | 15.06 | 14 | 22233 | 118 | 29552162 |
Carotid artery stenosis | 55.13 | 15.06 | 37 | 22210 | 4432 | 29547848 |
Thrombocytopenia | 52.10 | 15.06 | 220 | 22027 | 134603 | 29417677 |
Arteriosclerosis | 51.20 | 15.06 | 50 | 22197 | 10206 | 29542074 |
Peripheral artery occlusion | 51.10 | 15.06 | 24 | 22223 | 1438 | 29550842 |
Arterial stenosis | 50.38 | 15.06 | 22 | 22225 | 1111 | 29551169 |
Splenomegaly | 48.86 | 15.06 | 55 | 22192 | 13224 | 29539056 |
Concomitant disease progression | 48.27 | 15.06 | 27 | 22220 | 2334 | 29549946 |
Exposure via father | 46.48 | 15.06 | 12 | 22235 | 111 | 29552169 |
Bone pain | 44.73 | 15.06 | 62 | 22185 | 18390 | 29533890 |
Pruritus | 44.60 | 15.06 | 190 | 22057 | 116659 | 29435621 |
Blast cell crisis | 44.25 | 15.06 | 11 | 22236 | 86 | 29552194 |
Gene mutation | 42.38 | 15.06 | 19 | 22228 | 1022 | 29551258 |
Labelled drug-food interaction medication error | 41.09 | 15.06 | 9 | 22238 | 37 | 29552243 |
Confusional state | 38.99 | 15.06 | 24 | 22223 | 127853 | 29424427 |
Loss of therapeutic response | 38.87 | 15.06 | 13 | 22234 | 313 | 29551967 |
Drug interaction | 38.07 | 15.06 | 56 | 22191 | 197329 | 29354951 |
Overdose | 35.98 | 15.06 | 8 | 22239 | 79811 | 29472469 |
Peripheral ischaemia | 33.42 | 15.06 | 29 | 22218 | 5090 | 29547190 |
Angina unstable | 33.32 | 15.06 | 41 | 22206 | 10824 | 29541456 |
Myalgia | 32.69 | 15.06 | 126 | 22121 | 73893 | 29478387 |
Amylase increased | 32.64 | 15.06 | 29 | 22218 | 5251 | 29547029 |
Cerebral infarction | 32.60 | 15.06 | 63 | 22184 | 24612 | 29527668 |
Fall | 32.49 | 15.06 | 52 | 22195 | 177126 | 29375154 |
Infarction | 32.14 | 15.06 | 21 | 22226 | 2405 | 29549875 |
Paternal exposure during pregnancy | 30.92 | 15.06 | 6 | 22241 | 11 | 29552269 |
Blood glucose increased | 29.90 | 15.06 | 105 | 22142 | 58879 | 29493401 |
Hyperglycaemia | 29.84 | 15.06 | 74 | 22173 | 34213 | 29518067 |
Condition aggravated | 28.68 | 15.06 | 41 | 22206 | 146254 | 29406026 |
Cerebral artery stenosis | 28.27 | 15.06 | 10 | 22237 | 286 | 29551994 |
Cerebrovascular accident | 27.72 | 15.06 | 123 | 22124 | 76788 | 29475492 |
Drug hypersensitivity | 26.81 | 15.06 | 9 | 22238 | 68397 | 29483883 |
Hypercholesterolaemia | 26.66 | 15.06 | 30 | 22217 | 7208 | 29545072 |
Tremor | 26.60 | 15.06 | 11 | 22236 | 73527 | 29478753 |
Acoustic neuroma | 26.05 | 15.06 | 8 | 22239 | 145 | 29552135 |
Chronic myeloid leukaemia | 25.78 | 15.06 | 17 | 22230 | 1977 | 29550303 |
Dehydration | 25.76 | 15.06 | 29 | 22218 | 114719 | 29437561 |
Leukocytosis | 25.54 | 15.06 | 52 | 22195 | 21090 | 29531190 |
Pancreatic toxicity | 24.77 | 15.06 | 4 | 22243 | 0 | 29552280 |
Coronary artery occlusion | 24.58 | 15.06 | 34 | 22213 | 10060 | 29542220 |
Pericardial effusion | 24.25 | 15.06 | 51 | 22196 | 21157 | 29531123 |
Somnolence | 24.25 | 15.06 | 21 | 22226 | 93934 | 29458346 |
Pain in extremity | 24.24 | 15.06 | 154 | 22093 | 110279 | 29442001 |
Ischaemia | 23.81 | 15.06 | 22 | 22225 | 4190 | 29548090 |
Gangrene | 23.78 | 15.06 | 22 | 22225 | 4196 | 29548084 |
Hallucination | 23.40 | 15.06 | 3 | 22244 | 44709 | 29507571 |
Therapeutic response decreased | 23.28 | 15.06 | 55 | 22192 | 24656 | 29527624 |
Hyponatraemia | 23.07 | 15.06 | 11 | 22236 | 67622 | 29484658 |
Arterial thrombosis | 23.02 | 15.06 | 14 | 22233 | 1414 | 29550866 |
Clonal evolution | 22.89 | 15.06 | 7 | 22240 | 125 | 29552155 |
Fatigue | 22.34 | 15.06 | 348 | 21899 | 316473 | 29235807 |
Central nervous system leukaemia | 21.74 | 15.06 | 8 | 22239 | 257 | 29552023 |
Product blister packaging issue | 21.53 | 15.06 | 6 | 22241 | 76 | 29552204 |
Gamma-glutamyltransferase increased | 21.49 | 15.06 | 56 | 22191 | 26681 | 29525599 |
Agitation | 21.45 | 15.06 | 6 | 22241 | 51298 | 29500982 |
Basophil count increased | 20.75 | 15.06 | 9 | 22238 | 447 | 29551833 |
Necrosis | 20.52 | 15.06 | 22 | 22225 | 5008 | 29547272 |
Arteritis | 20.37 | 15.06 | 8 | 22239 | 308 | 29551972 |
Diabetes mellitus | 20.26 | 15.06 | 71 | 22176 | 39760 | 29512520 |
Chloroma | 20.20 | 15.06 | 9 | 22238 | 477 | 29551803 |
Blast cells present | 20.11 | 15.06 | 9 | 22238 | 482 | 29551798 |
Myeloproliferative neoplasm | 19.95 | 15.06 | 9 | 22238 | 491 | 29551789 |
Hepatic infection | 19.62 | 15.06 | 9 | 22238 | 511 | 29551769 |
Gelatinous transformation of the bone marrow | 19.49 | 15.06 | 4 | 22243 | 11 | 29552269 |
Acne | 19.44 | 15.06 | 29 | 22218 | 9191 | 29543089 |
Atrial fibrillation | 19.40 | 15.06 | 141 | 22106 | 105505 | 29446775 |
Chest discomfort | 19.25 | 15.06 | 77 | 22170 | 45906 | 29506374 |
Intentional overdose | 19.19 | 15.06 | 3 | 22244 | 38525 | 29513755 |
Abdominal pain | 19.07 | 15.06 | 170 | 22077 | 135187 | 29417093 |
B-cell small lymphocytic lymphoma | 19.03 | 15.06 | 6 | 22241 | 119 | 29552161 |
Muscle spasms | 19.03 | 15.06 | 98 | 22149 | 64984 | 29487296 |
Febrile neutropenia | 18.67 | 15.06 | 35 | 22212 | 112205 | 29440075 |
Rectosigmoid cancer | 17.69 | 15.06 | 6 | 22241 | 151 | 29552129 |
Leukaemia recurrent | 17.67 | 15.06 | 12 | 22235 | 1465 | 29550815 |
Delirium | 17.64 | 15.06 | 4 | 22243 | 39393 | 29512887 |
Arterial occlusive disease | 17.46 | 15.06 | 18 | 22229 | 3916 | 29548364 |
Acquired gene mutation | 16.93 | 15.06 | 11 | 22236 | 1247 | 29551033 |
Vascular stenosis | 16.82 | 15.06 | 6 | 22241 | 176 | 29552104 |
Bone marrow failure | 16.70 | 15.06 | 52 | 22195 | 27397 | 29524883 |
Cytopenia | 16.63 | 15.06 | 28 | 22219 | 9831 | 29542449 |
Intentional product misuse | 16.60 | 15.06 | 3 | 22244 | 34658 | 29517622 |
Seizure | 16.41 | 15.06 | 28 | 22219 | 93095 | 29459185 |
Cardiovascular disorder | 15.90 | 15.06 | 26 | 22221 | 8909 | 29543371 |
Oxygen saturation decreased | 15.80 | 15.06 | 7 | 22240 | 44930 | 29507350 |
Haemoglobin decreased | 15.71 | 15.06 | 137 | 22110 | 108238 | 29444042 |
Carotid arteriosclerosis | 15.60 | 15.06 | 11 | 22236 | 1427 | 29550853 |
Liver disorder | 15.45 | 15.06 | 51 | 22196 | 27698 | 29524582 |
Headache | 15.36 | 15.06 | 199 | 22048 | 173808 | 29378472 |
Alopecia | 15.36 | 15.06 | 40 | 22207 | 19044 | 29533236 |
Prinzmetal angina | 15.35 | 15.06 | 9 | 22238 | 850 | 29551430 |
Aggression | 15.15 | 15.06 | 4 | 22243 | 35537 | 29516743 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cytogenetic analysis abnormal | 733.20 | 14.70 | 151 | 28438 | 830 | 64469313 |
Peripheral arterial occlusive disease | 443.29 | 14.70 | 152 | 28437 | 6835 | 64463308 |
Electrocardiogram QT prolonged | 413.99 | 14.70 | 316 | 28273 | 79132 | 64391011 |
Blast crisis in myelogenous leukaemia | 407.78 | 14.70 | 90 | 28499 | 719 | 64469424 |
Second primary malignancy | 399.65 | 14.70 | 164 | 28425 | 12173 | 64457970 |
Drug resistance | 314.16 | 14.70 | 195 | 28394 | 34907 | 64435236 |
Pleural effusion | 294.52 | 14.70 | 320 | 28269 | 126239 | 64343904 |
Chronic myeloid leukaemia transformation | 245.12 | 14.70 | 48 | 28541 | 194 | 64469949 |
Lipase increased | 241.60 | 14.70 | 121 | 28468 | 14281 | 64455862 |
Rash | 214.09 | 14.70 | 561 | 28028 | 457988 | 64012155 |
Philadelphia chromosome positive | 210.74 | 14.70 | 50 | 28539 | 567 | 64469576 |
Intermittent claudication | 191.96 | 14.70 | 66 | 28523 | 2988 | 64467155 |
Angina pectoris | 180.78 | 14.70 | 154 | 28435 | 44927 | 64425216 |
Myocardial infarction | 178.25 | 14.70 | 287 | 28302 | 165534 | 64304609 |
Blood bilirubin increased | 170.76 | 14.70 | 166 | 28423 | 57387 | 64412756 |
Platelet count decreased | 159.79 | 14.70 | 275 | 28314 | 167436 | 64302707 |
Death | 159.20 | 14.70 | 522 | 28067 | 482183 | 63987960 |
Peripheral artery stenosis | 133.07 | 14.70 | 40 | 28549 | 1169 | 64468974 |
Malignant neoplasm progression | 128.96 | 14.70 | 201 | 28388 | 112670 | 64357473 |
Off label use | 125.75 | 14.70 | 62 | 28527 | 632744 | 63837399 |
Acute myocardial infarction | 119.71 | 14.70 | 151 | 28438 | 69567 | 64400576 |
White blood cell count increased | 110.20 | 14.70 | 141 | 28448 | 65873 | 64404270 |
Chronic myeloid leukaemia recurrent | 107.24 | 14.70 | 25 | 28564 | 261 | 64469882 |
Pancreatitis | 100.57 | 14.70 | 128 | 28461 | 59479 | 64410664 |
Bone pain | 96.26 | 14.70 | 112 | 28477 | 47460 | 64422683 |
Coronary artery stenosis | 91.82 | 14.70 | 59 | 28530 | 11189 | 64458954 |
Myocardial ischaemia | 90.26 | 14.70 | 78 | 28511 | 23173 | 64446970 |
Thrombocytopenia | 90.18 | 14.70 | 260 | 28329 | 223541 | 64246602 |
Arterial disorder | 86.86 | 14.70 | 32 | 28557 | 1773 | 64468370 |
Acute coronary syndrome | 83.63 | 14.70 | 69 | 28520 | 19241 | 64450902 |
Toxicity to various agents | 81.00 | 14.70 | 30 | 28559 | 363483 | 64106660 |
Gene mutation identification test positive | 75.87 | 14.70 | 18 | 28571 | 204 | 64469939 |
Arteriosclerosis | 75.67 | 14.70 | 60 | 28529 | 15817 | 64454326 |
Hypotension | 74.49 | 14.70 | 38 | 28551 | 380936 | 64089207 |
Carotid artery stenosis | 73.22 | 14.70 | 45 | 28544 | 7896 | 64462247 |
Acute kidney injury | 72.45 | 14.70 | 56 | 28533 | 449184 | 64020959 |
Polymerase chain reaction positive | 70.97 | 14.70 | 18 | 28571 | 274 | 64469869 |
Splenomegaly | 67.18 | 14.70 | 59 | 28530 | 17902 | 64452241 |
Blood glucose increased | 66.20 | 14.70 | 139 | 28450 | 97934 | 64372209 |
Acute lymphocytic leukaemia recurrent | 65.07 | 14.70 | 33 | 28556 | 3993 | 64466150 |
Pruritus | 63.25 | 14.70 | 290 | 28299 | 312110 | 64158033 |
Coronary artery disease | 62.61 | 14.70 | 103 | 28486 | 60330 | 64409813 |
Condition aggravated | 61.84 | 14.70 | 45 | 28544 | 372381 | 64097762 |
Myalgia | 61.63 | 14.70 | 182 | 28407 | 158435 | 64311708 |
Peripheral vascular disorder | 61.53 | 14.70 | 39 | 28550 | 7222 | 64462921 |
Pericardial effusion | 54.99 | 14.70 | 77 | 28512 | 39177 | 64430966 |
Rheumatoid arthritis | 54.51 | 14.70 | 5 | 28584 | 164289 | 64305854 |
Cerebral infarction | 52.35 | 14.70 | 77 | 28512 | 40967 | 64429176 |
Hyperbilirubinaemia | 51.61 | 14.70 | 55 | 28534 | 21150 | 64448993 |
Amylase increased | 51.37 | 14.70 | 39 | 28550 | 9646 | 64460497 |
Abdominal pain upper | 50.11 | 14.70 | 181 | 28408 | 174849 | 64295294 |
Hyperglycaemia | 49.04 | 14.70 | 93 | 28496 | 60875 | 64409268 |
Concomitant disease progression | 47.66 | 14.70 | 25 | 28564 | 3244 | 64466899 |
Concomitant disease aggravated | 47.40 | 14.70 | 40 | 28549 | 11502 | 64458641 |
Arterial stenosis | 46.84 | 14.70 | 19 | 28570 | 1366 | 64468777 |
Confusional state | 46.74 | 14.70 | 29 | 28560 | 261115 | 64209028 |
Gamma-glutamyltransferase increased | 46.67 | 14.70 | 80 | 28509 | 48430 | 64421713 |
Haemoglobin decreased | 46.24 | 14.70 | 190 | 28399 | 194873 | 64275270 |
Blast cell crisis | 45.41 | 14.70 | 11 | 28578 | 137 | 64470006 |
Peripheral artery occlusion | 45.02 | 14.70 | 21 | 28568 | 2117 | 64468026 |
Chest pain | 44.72 | 14.70 | 215 | 28374 | 235765 | 64234378 |
Joint swelling | 44.31 | 14.70 | 20 | 28569 | 215362 | 64254781 |
Bone marrow failure | 43.43 | 14.70 | 77 | 28512 | 47875 | 64422268 |
Gene mutation | 42.45 | 14.70 | 20 | 28569 | 2062 | 64468081 |
Drug hypersensitivity | 41.74 | 14.70 | 27 | 28562 | 237788 | 64232355 |
Overdose | 41.23 | 14.70 | 10 | 28579 | 159556 | 64310587 |
Acquired gene mutation | 40.25 | 14.70 | 19 | 28570 | 1967 | 64468176 |
Therapeutic response delayed | 40.10 | 14.70 | 15 | 28574 | 867 | 64469276 |
Pancytopenia | 39.99 | 14.70 | 147 | 28442 | 143162 | 64326981 |
Drug ineffective | 37.57 | 14.70 | 219 | 28370 | 840028 | 63630115 |
Arterial occlusive disease | 36.59 | 14.70 | 28 | 28561 | 7005 | 64463138 |
Peripheral ischaemia | 36.40 | 14.70 | 30 | 28559 | 8348 | 64461795 |
Platelet count increased | 36.11 | 14.70 | 43 | 28546 | 18653 | 64451490 |
Chronic myeloid leukaemia | 35.99 | 14.70 | 21 | 28568 | 3353 | 64466790 |
Acne | 34.92 | 14.70 | 47 | 28542 | 23034 | 64447109 |
Fall | 33.17 | 14.70 | 86 | 28503 | 416740 | 64053403 |
Leukaemia recurrent | 32.67 | 14.70 | 18 | 28571 | 2576 | 64467567 |
Cerebrovascular accident | 32.57 | 14.70 | 134 | 28455 | 137449 | 64332694 |
Hypercholesterolaemia | 32.43 | 14.70 | 37 | 28552 | 15336 | 64454807 |
Drug intolerance | 31.86 | 14.70 | 166 | 28423 | 187826 | 64282317 |
Therapeutic response decreased | 31.80 | 14.70 | 71 | 28518 | 52117 | 64418026 |
Gangrene | 31.31 | 14.70 | 26 | 28563 | 7312 | 64462831 |
Labelled drug-food interaction medication error | 30.87 | 14.70 | 7 | 28582 | 64 | 64470079 |
Hyponatraemia | 30.14 | 14.70 | 14 | 28575 | 148325 | 64321818 |
Dry skin | 29.39 | 14.70 | 68 | 28521 | 51093 | 64419050 |
Cerebral artery stenosis | 29.21 | 14.70 | 11 | 28578 | 648 | 64469495 |
Drug interaction | 28.56 | 14.70 | 75 | 28514 | 362008 | 64108135 |
Blood lactate dehydrogenase increased | 28.52 | 14.70 | 52 | 28537 | 33026 | 64437117 |
Angiopathy | 28.41 | 14.70 | 23 | 28566 | 6242 | 64463901 |
Anaemia | 28.32 | 14.70 | 274 | 28315 | 378406 | 64091737 |
Cardiac failure | 28.29 | 14.70 | 125 | 28464 | 132248 | 64337895 |
Abdominal pain | 27.94 | 14.70 | 235 | 28354 | 312140 | 64158003 |
Atrial fibrillation | 27.56 | 14.70 | 149 | 28440 | 170940 | 64299203 |
Pancreatic toxicity | 27.50 | 14.70 | 5 | 28584 | 12 | 64470131 |
Diabetes mellitus | 27.44 | 14.70 | 78 | 28511 | 66396 | 64403747 |
Oxygen saturation decreased | 27.13 | 14.70 | 7 | 28582 | 107169 | 64362974 |
Clonal evolution | 27.07 | 14.70 | 8 | 28581 | 220 | 64469923 |
Chronic myeloid leukaemia (in remission) | 26.89 | 14.70 | 4 | 28585 | 0 | 64470143 |
Arthropathy | 26.86 | 14.70 | 10 | 28579 | 120957 | 64349186 |
Keratosis pilaris | 26.64 | 14.70 | 6 | 28583 | 53 | 64470090 |
White blood cell count decreased | 26.47 | 14.70 | 139 | 28450 | 157698 | 64312445 |
Pain in extremity | 26.04 | 14.70 | 226 | 28363 | 302859 | 64167284 |
Alanine aminotransferase increased | 25.81 | 14.70 | 126 | 28463 | 138905 | 64331238 |
Angina unstable | 25.73 | 14.70 | 33 | 28556 | 15434 | 64454709 |
Haematotoxicity | 25.46 | 14.70 | 30 | 28559 | 12866 | 64457277 |
Xanthelasma | 24.96 | 14.70 | 7 | 28582 | 159 | 64469984 |
Muscle spasms | 24.90 | 14.70 | 126 | 28463 | 140897 | 64329246 |
Palpitations | 24.90 | 14.70 | 102 | 28487 | 104386 | 64365757 |
Hypersensitivity | 24.12 | 14.70 | 31 | 28558 | 196421 | 64273722 |
Leukocytosis | 23.73 | 14.70 | 52 | 28537 | 37688 | 64432455 |
Infarction | 23.36 | 14.70 | 17 | 28572 | 3943 | 64466200 |
Hepatic function abnormal | 23.25 | 14.70 | 72 | 28517 | 64241 | 64405902 |
Hepatic infection | 23.13 | 14.70 | 10 | 28579 | 843 | 64469300 |
Central nervous system leukaemia | 22.95 | 14.70 | 8 | 28581 | 377 | 64469766 |
Sinusitis | 22.44 | 14.70 | 19 | 28570 | 145909 | 64324234 |
Liver disorder | 22.41 | 14.70 | 63 | 28526 | 53288 | 64416855 |
Therapy non-responder | 22.20 | 14.70 | 72 | 28517 | 65827 | 64404316 |
Basophil count increased | 22.02 | 14.70 | 11 | 28578 | 1289 | 64468854 |
Intentional product misuse | 21.95 | 14.70 | 3 | 28586 | 72292 | 64397851 |
Exposure during pregnancy | 21.84 | 14.70 | 4 | 28585 | 77671 | 64392472 |
Urinary tract infection | 21.44 | 14.70 | 44 | 28545 | 231552 | 64238591 |
Loss of therapeutic response | 21.18 | 14.70 | 7 | 28582 | 280 | 64469863 |
Cytopenia | 21.14 | 14.70 | 30 | 28559 | 15441 | 64454702 |
Haemolytic transfusion reaction | 21.11 | 14.70 | 4 | 28585 | 13 | 64470130 |
Vascular stenosis | 21.07 | 14.70 | 8 | 28581 | 482 | 64469661 |
Coronary artery occlusion | 20.57 | 14.70 | 28 | 28561 | 13863 | 64456280 |
Arterial thrombosis | 20.46 | 14.70 | 13 | 28576 | 2417 | 64467726 |
Splenitis | 20.17 | 14.70 | 3 | 28586 | 0 | 64470143 |
Agitation | 20.13 | 14.70 | 7 | 28582 | 88360 | 64381783 |
Thrombocytosis | 20.01 | 14.70 | 20 | 28569 | 7136 | 64463007 |
Paternal exposure during pregnancy | 19.73 | 14.70 | 4 | 28585 | 20 | 64470123 |
Myeloproliferative neoplasm | 19.55 | 14.70 | 9 | 28580 | 880 | 64469263 |
Necrosis | 19.54 | 14.70 | 21 | 28568 | 8150 | 64461993 |
Somnolence | 19.44 | 14.70 | 38 | 28551 | 203607 | 64266536 |
Exposure via father | 19.42 | 14.70 | 5 | 28584 | 81 | 64470062 |
Blast cell count increased | 19.27 | 14.70 | 10 | 28579 | 1269 | 64468874 |
Suicide attempt | 19.24 | 14.70 | 4 | 28585 | 71003 | 64399140 |
Mobility decreased | 19.22 | 14.70 | 7 | 28582 | 85833 | 64384310 |
Dyslipidaemia | 19.08 | 14.70 | 22 | 28567 | 9220 | 64460923 |
Chromosome analysis abnormal | 18.71 | 14.70 | 6 | 28583 | 218 | 64469925 |
Tremor | 18.59 | 14.70 | 23 | 28566 | 148207 | 64321936 |
Skin disorder | 18.38 | 14.70 | 39 | 28550 | 27641 | 64442502 |
Acoustic neuroma | 18.38 | 14.70 | 6 | 28583 | 231 | 64469912 |
Chloroma | 18.26 | 14.70 | 8 | 28581 | 697 | 64469446 |
Ischaemic stroke | 18.24 | 14.70 | 40 | 28549 | 28995 | 64441148 |
Normal newborn | 18.15 | 14.70 | 17 | 28572 | 5600 | 64464543 |
Pyrexia | 17.88 | 14.70 | 347 | 28242 | 558297 | 63911846 |
Product use issue | 17.54 | 14.70 | 25 | 28564 | 151690 | 64318453 |
Suicidal ideation | 17.51 | 14.70 | 4 | 28585 | 66538 | 64403605 |
Metabolic acidosis | 17.27 | 14.70 | 5 | 28584 | 70953 | 64399190 |
Blood creatine phosphokinase increased | 17.10 | 14.70 | 61 | 28528 | 58497 | 64411646 |
Transformation to acute myeloid leukaemia | 16.72 | 14.70 | 8 | 28581 | 853 | 64469290 |
Musculoskeletal stiffness | 16.66 | 14.70 | 18 | 28571 | 123188 | 64346955 |
Delirium | 16.61 | 14.70 | 5 | 28584 | 69189 | 64400954 |
Intentional product use issue | 16.48 | 14.70 | 11 | 28578 | 95353 | 64374790 |
Lower respiratory tract infection | 16.23 | 14.70 | 11 | 28578 | 94603 | 64375540 |
Aspartate aminotransferase increased | 15.81 | 14.70 | 99 | 28490 | 119689 | 64350454 |
Dyslalia | 15.70 | 14.70 | 8 | 28581 | 977 | 64469166 |
Peripheral artery thrombosis | 15.68 | 14.70 | 12 | 28577 | 3003 | 64467140 |
Hepatotoxicity | 15.63 | 14.70 | 46 | 28543 | 39916 | 64430227 |
Supraventricular extrasystoles | 15.56 | 14.70 | 16 | 28573 | 5899 | 64464244 |
Vertebral artery stenosis | 15.53 | 14.70 | 5 | 28584 | 184 | 64469959 |
Febrile neutropenia | 15.45 | 14.70 | 38 | 28551 | 187619 | 64282524 |
Coma | 15.28 | 14.70 | 10 | 28579 | 87605 | 64382538 |
Glossodynia | 14.95 | 14.70 | 5 | 28584 | 64691 | 64405452 |
None
Source | Code | Description |
---|---|---|
ATC | L01EA03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS BCR-ABL tyrosine kinase inhibitors |
FDA MoA | N0000020009 | Bcr-Abl Tyrosine Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
FDA MoA | N0000187062 | Cytochrome P450 2C8 Inhibitors |
FDA MoA | N0000187063 | Cytochrome P450 2C8 Inducers |
FDA MoA | N0000187064 | Cytochrome P450 2B6 Inducers |
FDA MoA | N0000191272 | UGT1A1 Inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:38637 | tyrosine kinase inhibitors |
CHEBI has role | CHEBI:149553 | anticoronaviral drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic phase chronic myeloid leukemia | indication | 413847001 | |
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia | indication | ||
Chronic Myelocytic Leukemia Accelerated Phase | indication | ||
Hypophosphatemia | contraindication | 4996001 | |
Hypocalcemia | contraindication | 5291005 | |
Hypercholesterolemia | contraindication | 13644009 | |
Hyperkalemia | contraindication | 14140009 | |
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Torsades de pointes | contraindication | 31722008 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hypokalemia | contraindication | 43339004 | |
Gastrectomy | contraindication | 53442002 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Hyponatremia | contraindication | 89627008 | |
Prolonged QT interval | contraindication | 111975006 | |
Liver function tests abnormal | contraindication | 166603001 | |
Hypomagnesemia | contraindication | 190855004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Breastfeeding (mother) | contraindication | 413712001 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Elevated Serum Lipase | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.89 | acidic |
pKa2 | 6.03 | Basic |
pKa3 | 3.97 | Basic |
pKa4 | 2.2 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | 7169791 | July 4, 2023 | A METHOD FOR THE TREATMENT OF LEUKEMIAS |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | 8389537 | July 18, 2026 | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | 8415363 | July 18, 2026 | TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML) |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | 8415363 | July 18, 2026 | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | 9061029 | April 7, 2032 | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | 9061029 | April 7, 2032 | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | March 22, 2025 | TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | March 22, 2025 | TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | Sept. 22, 2025 | PEDIATRIC EXCLUSIVITY |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | Sept. 23, 2028 | TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE ORINTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY |
EQ 50MG BASE | TASIGNA | NOVARTIS | N022068 | March 22, 2018 | RX | CAPSULE | ORAL | March 23, 2029 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase ABL1 | Kinase | INHIBITOR | Kd | 8.44 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 2 | Enzyme | Ki | 8.39 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 7.53 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 6.35 | CHEMBL | |||||
Ribosyldihydronicotinamide dehydrogenase [quinone] | Enzyme | IC50 | 6.42 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 7.38 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 6.52 | CHEMBL | |||||
Platelet-derived growth factor receptor beta | Kinase | Kd | 7.80 | CHEMBL | |||||
Mast/stem cell growth factor receptor Kit | Kinase | Kd | 7.77 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 5.26 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 4.83 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 7 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | Kd | 5.72 | CHEMBL | |||||
Tyrosine-protein kinase Lck | Kinase | Kd | 7.33 | CHEMBL | |||||
Tyrosine-protein kinase Yes | Kinase | Kd | 5.96 | CHEMBL | |||||
Tyrosine-protein kinase Fyn | Kinase | Kd | 5.80 | CHEMBL | |||||
Ephrin type-A receptor 2 | Kinase | Kd | 6.64 | CHEMBL | |||||
RAF proto-oncogene serine/threonine-protein kinase | Kinase | Kd | 5.41 | CHEMBL | |||||
Serine/threonine-protein kinase B-raf | Kinase | Kd | 6.24 | CHEMBL | |||||
Receptor-type tyrosine-protein kinase FLT3 | Kinase | Kd | 4.40 | CHEMBL | |||||
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | Kd | 6.06 | CHEMBL | |||||
Macrophage colony-stimulating factor 1 receptor | Kinase | Kd | 7.35 | CHEMBL | |||||
Platelet-derived growth factor receptor alpha | Kinase | Kd | 7.13 | CHEMBL | |||||
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Kinase | Kd | 6.48 | CHEMBL | |||||
Insulin receptor | Kinase | Ki | 5.39 | PDSP | |||||
Mitogen-activated protein kinase 8 | Kinase | Kd | 6.35 | CHEMBL | |||||
Tyrosine-protein kinase HCK | Kinase | Kd | 6.41 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 6.35 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 6.34 | CHEMBL | |||||
Mitogen-activated protein kinase 10 | Kinase | Kd | 5.70 | CHEMBL | |||||
Tyrosine-protein kinase JAK2 | Kinase | Ki | 5.07 | PDSP | |||||
Tyrosine-protein kinase CSK | Kinase | Kd | 5.62 | CHEMBL | |||||
Angiopoietin-1 receptor | Kinase | Kd | 6 | CHEMBL | |||||
Ephrin type-A receptor 8 | Kinase | Kd | 7.43 | CHEMBL | |||||
Tyrosine-protein kinase Lyn | Kinase | Kd | 7 | CHEMBL | |||||
Cytoplasmic tyrosine-protein kinase BMX | Kinase | Ki | 5.32 | PDSP | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 6.65 | CHEMBL | |||||
Fibroblast growth factor receptor 1 | Kinase | Ki | 5.10 | PDSP | |||||
Serine/threonine-protein kinase 10 | Kinase | Kd | 5.17 | CHEMBL | |||||
Abelson tyrosine-protein kinase 2 | Kinase | Kd | 7.59 | CHEMBL | |||||
Mitogen-activated protein kinase 11 | Kinase | Kd | 7.44 | CHEMBL | |||||
Ephrin type-A receptor 5 | Kinase | Kd | 5.72 | CHEMBL | |||||
Ephrin type-A receptor 4 | Kinase | Kd | 6.48 | CHEMBL | |||||
Fibroblast growth factor receptor 2 | Kinase | Ki | 5.14 | PDSP | |||||
Ephrin type-A receptor 6 | Kinase | Kd | 6.19 | CHEMBL | |||||
Tyrosine-protein kinase Fgr | Kinase | Kd | 6.49 | CHEMBL | |||||
Ephrin type-A receptor 3 | Kinase | Kd | 6.96 | CHEMBL | |||||
Mitogen-activated protein kinase 14 | Kinase | Kd | 6.34 | CHEMBL | |||||
Tyrosine-protein kinase FRK | Kinase | Kd | 7.07 | CHEMBL | |||||
Dual specificity protein kinase CLK1 | Kinase | Kd | 5.68 | CHEMBL | |||||
Ephrin type-B receptor 1 | Kinase | Kd | 5.89 | CHEMBL | |||||
Dual specificity protein kinase CLK4 | Kinase | Kd | 5.15 | CHEMBL | |||||
Mitogen-activated protein kinase 9 | Kinase | Kd | 5.24 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 8.96 | CHEMBL | |||||
Ephrin type-B receptor 4 | Kinase | Kd | 6.14 | CHEMBL | |||||
BDNF/NT-3 growth factors receptor | Kinase | Kd | 6.31 | CHEMBL | |||||
Ephrin type-B receptor 2 | Kinase | Kd | 6.19 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase MLT | Kinase | Kd | 7.96 | CHEMBL | |||||
Tyrosine-protein kinase receptor Tie-1 | Kinase | Kd | 6 | CHEMBL | |||||
NT-3 growth factor receptor | Kinase | Kd | 6.22 | CHEMBL | |||||
Serine/threonine-protein kinase TNNI3K | Kinase | Kd | 6.44 | CHEMBL | |||||
Discoidin domain-containing receptor 2 | Kinase | Kd | 8.22 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 1 | Kinase | Kd | 6.05 | CHEMBL | |||||
Tyrosine-protein kinase Blk | Kinase | Kd | 6.30 | CHEMBL | |||||
Serine/threonine-protein kinase MRCK beta | Kinase | Kd | 6.04 | CHEMBL | |||||
Ephrin type-A receptor 1 | Kinase | Kd | 6.23 | CHEMBL | |||||
Ephrin type-B receptor 3 | Kinase | Kd | 6 | CHEMBL | |||||
Ephrin type-B receptor 6 | Kinase | Kd | 6.30 | CHEMBL | |||||
Serine/threonine-protein kinase TAO1 | Kinase | Kd | 5.33 | CHEMBL | |||||
Serine/threonine-protein kinase TAO3 | Kinase | Kd | 5.77 | CHEMBL | |||||
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Kinase | Kd | 5.06 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 6.72 | CHEMBL | |||||
Bcr/Abl fusion protein | Kinase | IC50 | 9.48 | CHEMBL | |||||
Ferrochelatase, mitochondrial | Enzyme | Kd | 5.38 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 3 | Kinase | Kd | 5.89 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.35 | CHEMBL | |||||
Integrin-linked protein kinase | Kinase | Kd | 7.70 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 5.33 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 7.10 | CHEMBL | |||||
Calcium-dependent protein kinase 1 | Kinase | Kd | 6.10 | CHEMBL |
ID | Source |
---|---|
4026964 | VUID |
N0000176124 | NUI |
D06413 | KEGG_DRUG |
923288-90-8 | SECONDARY_CAS_RN |
4026964 | VANDF |
C1721377 | UMLSCUI |
CHEBI:52172 | CHEBI |
NIL | PDB_CHEM_ID |
CHEMBL255863 | ChEMBL_ID |
CHEMBL1201740 | ChEMBL_ID |
DB04868 | DRUGBANK_ID |
C498826 | MESH_SUPPLEMENTAL_RECORD_UI |
5697 | IUPHAR_LIGAND_ID |
8654 | INN_ID |
F41401512X | UNII |
644241 | PUBCHEM_CID |
662281 | RXNORM |
127956 | MMSL |
24733 | MMSL |
d07057 | MMSL |
012401 | NDDF |
427941004 | SNOMEDCT_US |
428468009 | SNOMEDCT_US |
438943005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tasigna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0526 | CAPSULE | 200 mg | ORAL | NDA | 33 sections |
Tasigna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0592 | CAPSULE | 150 mg | ORAL | NDA | 33 sections |
Tasigna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0951 | CAPSULE | 50 mg | ORAL | NDA | 33 sections |